Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors.

Pros E, Saigi M, Alameda D, Gomez-Mariano G, Martinez-Delgado B, Alburquerque-Bejar JJ, Carretero J, Tonda R, Esteve-Codina A, Catala I, Palmero R, Jove M, Lazaro C, Patiño-Garcia A, Gil-Bazo I, Verdura S, Teulé A, Torres-Lanzas J, Sidransky D, Reguart N, Pio R, Juan-Vidal O, Nadal E, Felip E, Montuenga LM, Sanchez-Cespedes M.

Ann Oncol. 2020 Feb;31(2):274-282. doi: 10.1016/j.annonc.2019.09.001.

PMID:
31959344
2.

TMPRSS4: A Novel Tumor Prognostic Indicator for the Stratification of Stage IA Tumors and a Liquid Biopsy Biomarker for NSCLC Patients.

Villalba M, Exposito F, Pajares MJ, Sainz C, Redrado M, Remirez A, Wistuba I, Behrens C, Jantus-Lewintre E, Camps C, Montuenga LM, Pio R, Lozano MD, de Andrea C, Calvo A.

J Clin Med. 2019 Dec 3;8(12). pii: E2134. doi: 10.3390/jcm8122134.

3.

The Differential Impact of SRC Expression on the Prognosis of Patients with Head and Neck Squamous Cell Carcinoma.

Hermida-Prado F, Granda-Díaz R, Del-Río-Ibisate N, Villaronga MÁ, Allonca E, Garmendia I, Montuenga LM, Rodríguez R, Vallina A, Alvarez-Marcos C, Rodrigo JP, García-Pedrero JM.

Cancers (Basel). 2019 Oct 25;11(11). pii: E1644. doi: 10.3390/cancers11111644.

4.

Epigenetic SMAD3 Repression in Tumor-Associated Fibroblasts Impairs Fibrosis and Response to the Antifibrotic Drug Nintedanib in Lung Squamous Cell Carcinoma.

Ikemori R, Gabasa M, Duch P, Vizoso M, Bragado P, Arshakyan M, Luis IC, Marín A, Morán S, Castro M, Fuster G, Gea-Sorli S, Jauset T, Soucek L, Montuenga LM, Esteller M, Monsó E, Peinado VI, Gascon P, Fillat C, Hilberg F, Reguart N, Alcaraz J.

Cancer Res. 2020 Jan 15;80(2):276-290. doi: 10.1158/0008-5472.CAN-19-0637. Epub 2019 Nov 6.

PMID:
31694906
5.

The SRC Inhibitor Dasatinib Induces Stem Cell-Like Properties in Head and Neck Cancer Cells that are Effectively Counteracted by the Mithralog EC-8042.

Hermida-Prado F, Villaronga MÁ, Granda-Díaz R, Del-Río-Ibisate N, Santos L, Hermosilla MA, Oro P, Allonca E, Agorreta J, Garmendia I, Tornín J, Perez-Escuredo J, Fuente R, Montuenga LM, Morís F, Rodrigo JP, Rodríguez R, García-Pedrero JM.

J Clin Med. 2019 Aug 2;8(8). pii: E1157. doi: 10.3390/jcm8081157.

6.

YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.

Garmendia I, Pajares MJ, Hermida-Prado F, Ajona D, Bértolo C, Sainz C, Lavín A, Remírez AB, Valencia K, Moreno H, Ferrer I, Behrens C, Cuadrado M, Paz-Ares L, Bustelo XR, Gil-Bazo I, Alameda D, Lecanda F, Calvo A, Felip E, Sánchez-Céspedes M, Wistuba II, Granda-Diaz R, Rodrigo JP, García-Pedrero JM, Pio R, Montuenga LM, Agorreta J.

Am J Respir Crit Care Med. 2019 Oct 1;200(7):888-899. doi: 10.1164/rccm.201807-1292OC.

PMID:
31166114
7.

Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery.

Exposito F, Villalba M, Redrado M, de Aberasturi AL, Cirauqui C, Redin E, Guruceaga E, de Andrea C, Vicent S, Ajona D, Montuenga LM, Pio R, Calvo A.

Cancer Lett. 2019 Jul 1;453:21-33. doi: 10.1016/j.canlet.2019.03.013. Epub 2019 Mar 21.

PMID:
30905815
8.

Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges.

Seijo LM, Peled N, Ajona D, Boeri M, Field JK, Sozzi G, Pio R, Zulueta JJ, Spira A, Massion PP, Mazzone PJ, Montuenga LM.

J Thorac Oncol. 2019 Mar;14(3):343-357. doi: 10.1016/j.jtho.2018.11.023. Epub 2018 Dec 4. Review.

9.

5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging.

Martínez-Terroba E, Behrens C, Agorreta J, Monsó E, Millares L, Felip E, Rosell R, Ramirez JL, Remirez A, Torre W, Gil-Bazo I, Idoate MA, de-Torres JP, Pio R, Wistuba II, Pajares MJ, Montuenga LM.

Thorax. 2019 Apr;74(4):371-379. doi: 10.1136/thoraxjnl-2018-212194. Epub 2018 Nov 24.

PMID:
30472670
10.

Comparison of RNA-seq and microarray platforms for splice event detection using a cross-platform algorithm.

Romero JP, Ortiz-Estévez M, Muniategui A, Carrancio S, de Miguel FJ, Carazo F, Montuenga LM, Loos R, Pío R, Trotter MWB, Rubio A.

BMC Genomics. 2018 Sep 25;19(1):703. doi: 10.1186/s12864-018-5082-2.

11.

The oncogenic RNA-binding protein SRSF1 regulates LIG1 in non-small cell lung cancer.

Martínez-Terroba E, Ezponda T, Bértolo C, Sainz C, Remírez A, Agorreta J, Garmendia I, Behrens C, Pio R, Wistuba II, Montuenga LM, Pajares MJ.

Lab Invest. 2018 Dec;98(12):1562-1574. doi: 10.1038/s41374-018-0128-2. Epub 2018 Sep 4.

12.

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.

Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V, Piñeyro D, Sanchez-Cespedes M, Girard N, Brevet M, Giroux-Leprieur E, Dumenil C, Pradotto M, Bironzo P, Capelletto E, Novello S, Cortot A, Copin MC, Karachaliou N, Gonzalez-Cao M, Peralta S, Montuenga LM, Gil-Bazo I, Baraibar I, Lozano MD, Varela M, Ruffinelli JC, Palmero R, Nadal E, Moran T, Perez L, Ramos I, Xiao Q, Fernandez AF, Fraga MF, Gut M, Gut I, Teixidó C, Vilariño N, Prat A, Reguart N, Benito A, Garrido P, Barragan I, Emile JF, Rosell R, Brambilla E, Esteller M.

Lancet Respir Med. 2018 Oct;6(10):771-781. doi: 10.1016/S2213-2600(18)30284-4. Epub 2018 Aug 9.

13.

Epistatic Oncogenic Interactions Determine Cancer Susceptibility to Immunotherapy.

Etxeberria I, Teijeira A, Montuenga LM, Berraondo P, Melero I.

Cancer Discov. 2018 Jul;8(7):794-796. doi: 10.1158/2159-8290.CD-18-0573.

14.

A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients.

Martínez-Terroba E, Behrens C, de Miguel FJ, Agorreta J, Monsó E, Millares L, Sainz C, Mesa-Guzman M, Pérez-Gracia JL, Lozano MD, Zulueta JJ, Pio R, Wistuba II, Montuenga LM, Pajares MJ.

J Pathol. 2018 Aug;245(4):421-432. doi: 10.1002/path.5096. Epub 2018 Jun 20.

15.

Complement C4d-specific antibodies for the diagnosis of lung cancer.

Ajona D, Okrój M, Pajares MJ, Agorreta J, Lozano MD, Zulueta JJ, Verri C, Roz L, Sozzi G, Pastorino U, Massion PP, Montuenga LM, Blom AM, Pio R.

Oncotarget. 2017 Dec 26;9(5):6346-6355. doi: 10.18632/oncotarget.23690. eCollection 2018 Jan 19.

16.

Ruthenium counterstaining for imaging mass cytometry.

Catena R, Montuenga LM, Bodenmiller B.

J Pathol. 2018 Apr;244(4):479-484. doi: 10.1002/path.5049. Epub 2018 Mar 6.

PMID:
29405336
17.

Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects.

Ajona D, Zandueta C, Corrales L, Moreno H, Pajares MJ, Ortiz-Espinosa S, Martínez-Terroba E, Perurena N, de Miguel FJ, Jantus-Lewintre E, Camps C, Vicent S, Agorreta J, Montuenga LM, Pio R, Lecanda F.

Am J Respir Crit Care Med. 2018 May 1;197(9):1164-1176. doi: 10.1164/rccm.201703-0660OC.

18.

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K.

Cancer Discov. 2017 Dec;7(12):1420-1435. doi: 10.1158/2159-8290.CD-17-0593. Epub 2017 Oct 12.

19.

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition.

Pereira C, Gimenez-Xavier P, Pros E, Pajares MJ, Moro M, Gomez A, Navarro A, Condom E, Moran S, Gomez-Lopez G, Graña O, Rubio-Camarillo M, Martinez-Martí A, Yokota J, Carretero J, Galbis JM, Nadal E, Pisano D, Sozzi G, Felip E, Montuenga LM, Roz L, Villanueva A, Sanchez-Cespedes M.

Clin Cancer Res. 2017 Jun 15;23(12):3203-3213. doi: 10.1158/1078-0432.CCR-16-1946. Epub 2017 Mar 16.

20.

A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis.

Ajona D, Ortiz-Espinosa S, Moreno H, Lozano T, Pajares MJ, Agorreta J, Bértolo C, Lasarte JJ, Vicent S, Hoehlig K, Vater A, Lecanda F, Montuenga LM, Pio R.

Cancer Discov. 2017 Jul;7(7):694-703. doi: 10.1158/2159-8290.CD-16-1184. Epub 2017 Mar 13.

21.

Strategies to design clinical studies to identify predictive biomarkers in cancer research.

Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I.

Cancer Treat Rev. 2017 Feb;53:79-97. doi: 10.1016/j.ctrv.2016.12.005. Epub 2016 Dec 30. Review.

22.

Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma.

Vallejo-Díaz J, Olazabal-Morán M, Cariaga-Martínez AE, Pajares MJ, Flores JM, Pio R, Montuenga LM, Carrera AC.

Oncotarget. 2016 Dec 20;7(51):85063-85078. doi: 10.18632/oncotarget.13195.

23.

A large-scale analysis of alternative splicing reveals a key role of QKI in lung cancer.

de Miguel FJ, Pajares MJ, Martínez-Terroba E, Ajona D, Morales X, Sharma RD, Pardo FJ, Rouzaut A, Rubio A, Montuenga LM, Pio R.

Mol Oncol. 2016 Nov;10(9):1437-1449. doi: 10.1016/j.molonc.2016.08.001. Epub 2016 Aug 9.

24.

Phenotypic and metabolic features of mouse diaphragm and gastrocnemius muscles in chronic lung carcinogenesis: influence of underlying emphysema.

Salazar-Degracia A, Blanco D, Vilà-Ubach M, de Biurrun G, de Solórzano CO, Montuenga LM, Barreiro E.

J Transl Med. 2016 Aug 23;14(1):244. doi: 10.1186/s12967-016-1003-9.

25.

Epigenetic alterations leading to TMPRSS4 promoter hypomethylation and protein overexpression predict poor prognosis in squamous lung cancer patients.

Villalba M, Diaz-Lagares A, Redrado M, de Aberasturi AL, Segura V, Bodegas ME, Pajares MJ, Pio R, Freire J, Gomez-Roman J, Montuenga LM, Esteller M, Sandoval J, Calvo A.

Oncotarget. 2016 Apr 19;7(16):22752-69. doi: 10.18632/oncotarget.8045.

26.

Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.

Azpilikueta A, Agorreta J, Labiano S, Pérez-Gracia JL, Sánchez-Paulete AR, Aznar MA, Ajona D, Gil-Bazo I, Larrayoz M, Teijeira A, Rodriguez-Ruiz ME, Pio R, Montuenga LM, Melero I.

J Thorac Oncol. 2016 Apr;11(4):524-36. doi: 10.1016/j.jtho.2016.01.013. Epub 2016 Feb 1.

27.

A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer.

Diaz-Lagares A, Mendez-Gonzalez J, Hervas D, Saigi M, Pajares MJ, Garcia D, Crujerias AB, Pio R, Montuenga LM, Zulueta J, Nadal E, Rosell A, Esteller M, Sandoval J.

Clin Cancer Res. 2016 Jul 1;22(13):3361-71. doi: 10.1158/1078-0432.CCR-15-2346. Epub 2016 Feb 3.

28.

Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations.

Aramburu A, Zudaire I, Pajares MJ, Agorreta J, Orta A, Lozano MD, Gúrpide A, Gómez-Román J, Martinez-Climent JA, Jassem J, Skrzypski M, Suraokar M, Behrens C, Wistuba II, Pio R, Rubio A, Montuenga LM.

BMC Genomics. 2015 Oct 6;16:752. doi: 10.1186/s12864-015-1935-0.

29.

Sphere-derived tumor cells exhibit impaired metastasis by a host-mediated quiescent phenotype.

Bleau AM, Zandueta C, Redrado M, Martínez-Canarias S, Larzábal L, Montuenga LM, Calvo A, Lecanda F.

Oncotarget. 2015 Sep 29;6(29):27288-303. doi: 10.18632/oncotarget.4803.

30.

Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma.

Ajona D, Pajares MJ, Chiara MD, Rodrigo JP, Jantus-Lewintre E, Camps C, Suarez C, Bagán JV, Montuenga LM, Pio R.

Oral Dis. 2015 Oct;21(7):899-904. doi: 10.1111/odi.12363. Epub 2015 Sep 7.

PMID:
26258989
31.

Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators.

Rakha E, Pajares MJ, Ilie M, Pio R, Echeveste J, Hughes E, Soomro I, Long E, Idoate MA, Wagner S, Lanchbury JS, Baldwin DR, Hofman P, Montuenga LM.

Eur J Cancer. 2015 Sep;51(14):1897-903. doi: 10.1016/j.ejca.2015.07.015. Epub 2015 Jul 30.

PMID:
26235745
32.

Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism-related genes.

Pio R, Agorreta J, Montuenga LM.

J Thorac Cardiovasc Surg. 2015 Oct;150(4):986-92.e1-11. doi: 10.1016/j.jtcvs.2015.06.001. Epub 2015 Jun 9.

33.

Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients.

Grbesa I, Pajares MJ, Martínez-Terroba E, Agorreta J, Mikecin AM, Larráyoz M, Idoate MA, Gall-Troselj K, Pio R, Montuenga LM.

PLoS One. 2015 Apr 27;10(4):e0124670. doi: 10.1371/journal.pone.0124670. eCollection 2015.

34.

Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer.

Ajona D, Razquin C, Pastor MD, Pajares MJ, Garcia J, Cardenal F, Fleischhacker M, Lozano MD, Zulueta JJ, Schmidt B, Nadal E, Paz-Ares L, Montuenga LM, Pio R.

PLoS One. 2015 Mar 23;10(3):e0119878. doi: 10.1371/journal.pone.0119878. eCollection 2015.

35.

Improving selection criteria for lung cancer screening. The potential role of emphysema.

Sanchez-Salcedo P, Wilson DO, de-Torres JP, Weissfeld JL, Berto J, Campo A, Alcaide AB, Pueyo J, Bastarrika G, Seijo LM, Pajares MJ, Pio R, Montuenga LM, Zulueta JJ.

Am J Respir Crit Care Med. 2015 Apr 15;191(8):924-31. doi: 10.1164/rccm.201410-1848OC.

36.

Lung cancer screening: fourteen year experience of the Pamplona early detection program (P-IELCAP).

Sanchez-Salcedo P, Berto J, de-Torres JP, Campo A, Alcaide AB, Bastarrika G, Pueyo JC, Villanueva A, Echeveste JI, Lozano MD, García-Velloso MJ, Seijo LM, García J, Torre W, Pajares MJ, Pío R, Montuenga LM, Zulueta JJ.

Arch Bronconeumol. 2015 Apr;51(4):169-76. doi: 10.1016/j.arbres.2014.09.019. Epub 2015 Jan 29. English, Spanish.

PMID:
25641356
37.

Biological Marker Analysis as Part of the CIBERES-RTIC Cancer-SEPAR Strategic Project on Lung Cancer.

Monsó E, Montuenga LM, Sánchez de Cos J, Villena C; Lung Cancer CIBERES-RTICC-SEPAR-Plataforma Biobanco Pulmonar.

Arch Bronconeumol. 2015 Sep;51(9):462-7. doi: 10.1016/j.arbres.2014.11.010. Epub 2015 Jan 19. English, Spanish.

PMID:
25614375
38.

TRAP1 regulates proliferation, mitochondrial function, and has prognostic significance in NSCLC.

Agorreta J, Hu J, Liu D, Delia D, Turley H, Ferguson DJ, Iborra F, Pajares MJ, Larrayoz M, Zudaire I, Pio R, Montuenga LM, Harris AL, Gatter K, Pezzella F.

Mol Cancer Res. 2014 May;12(5):660-9. doi: 10.1158/1541-7786.MCR-13-0481. Epub 2014 Feb 24.

39.

Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype.

Larrayoz M, Pio R, Pajares MJ, Zudaire I, Ajona D, Casanovas O, Montuenga LM, Agorreta J.

EMBO Mol Med. 2014 Apr;6(4):539-50. doi: 10.1002/emmm.201303214. Epub 2014 Feb 5.

40.

TGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients.

Pajares MJ, Agorreta J, Salvo E, Behrens C, Wistuba II, Montuenga LM, Pio R, Rouzaut A.

Br J Cancer. 2014 Mar 18;110(6):1545-51. doi: 10.1038/bjc.2014.33. Epub 2014 Jan 30.

41.

New syngeneic inflammatory-related lung cancer metastatic model harboring double KRAS/WWOX alterations.

Bleau AM, Freire J, Pajares MJ, Zudaire I, Anton I, Nistal-Villán E, Redrado M, Zandueta CN, Garmendia I, Ajona D, Blanco D, Pio R, Lecanda F, Calvo A, Montuenga LM.

Int J Cancer. 2014 Dec 1;135(11):2516-27. doi: 10.1002/ijc.28574. Epub 2014 Jan 28.

42.

TMPRSS4 regulates levels of integrin α5 in NSCLC through miR-205 activity to promote metastasis.

Larzabal L, de Aberasturi AL, Redrado M, Rueda P, Rodriguez MJ, Bodegas ME, Montuenga LM, Calvo A.

Br J Cancer. 2014 Feb 4;110(3):764-74. doi: 10.1038/bjc.2013.761. Epub 2014 Jan 16.

43.

Identification of alternative splicing events regulated by the oncogenic factor SRSF1 in lung cancer.

de Miguel FJ, Sharma RD, Pajares MJ, Montuenga LM, Rubio A, Pio R.

Cancer Res. 2014 Feb 15;74(4):1105-15. doi: 10.1158/0008-5472.CAN-13-1481. Epub 2013 Dec 26.

44.

MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1.

Romero OA, Torres-Diz M, Pros E, Savola S, Gomez A, Moran S, Saez C, Iwakawa R, Villanueva A, Montuenga LM, Kohno T, Yokota J, Sanchez-Cespedes M.

Cancer Discov. 2014 Mar;4(3):292-303. doi: 10.1158/2159-8290.CD-13-0799. Epub 2013 Dec 20.

45.

A prognostic DNA methylation signature for stage I non-small-cell lung cancer.

Sandoval J, Mendez-Gonzalez J, Nadal E, Chen G, Carmona FJ, Sayols S, Moran S, Heyn H, Vizoso M, Gomez A, Sanchez-Cespedes M, Assenov Y, Müller F, Bock C, Taron M, Mora J, Muscarella LA, Liloglou T, Davies M, Pollan M, Pajares MJ, Torre W, Montuenga LM, Brambilla E, Field JK, Roz L, Lo Iacono M, Scagliotti GV, Rosell R, Beer DG, Esteller M.

J Clin Oncol. 2013 Nov 10;31(32):4140-7. doi: 10.1200/JCO.2012.48.5516. Epub 2013 Sep 30.

46.

Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer.

Ajona D, Pajares MJ, Corrales L, Perez-Gracia JL, Agorreta J, Lozano MD, Torre W, Massion PP, de-Torres JP, Jantus-Lewintre E, Camps C, Zulueta JJ, Montuenga LM, Pio R.

J Natl Cancer Inst. 2013 Sep 18;105(18):1385-93. doi: 10.1093/jnci/djt205. Epub 2013 Aug 12.

47.

Individual nodule tracking in micro-CT images of a longitudinal lung cancer mouse model.

Rudyanto RD, Bastarrika G, de Biurrun G, Agorreta J, Montuenga LM, Ortiz-de-Solorzano C, Muñoz-Barrutia A.

Med Image Anal. 2013 Dec;17(8):1095-105. doi: 10.1016/j.media.2013.07.002. Epub 2013 Jul 19.

PMID:
23920346
48.

Silica-induced chronic inflammation promotes lung carcinogenesis in the context of an immunosuppressive microenvironment.

Freire J, Ajona D, de Biurrun G, Agorreta J, Segura V, Guruceaga E, Bleau AM, Pio R, Blanco D, Montuenga LM.

Neoplasia. 2013 Aug;15(8):913-24.

49.

Smokers with CT detected emphysema and no airway obstruction have decreased plasma levels of EGF, IL-15, IL-8 and IL-1ra.

de-Torres JP, Blanco D, Alcaide AB, Seijo LM, Bastarrika G, Pajares MJ, Muñoz-Barrutia A, Ortiz-de-Solorzano C, Pio R, Campo A, Montes U, Segura V, Pueyo J, Montuenga LM, Zulueta JJ.

PLoS One. 2013;8(4):e60260. doi: 10.1371/journal.pone.0060260. Epub 2013 Apr 5.

50.

Multiscale in situ analysis of the role of dyskerin in lung cancer cells.

Fernandez-Garcia I, Marcos T, Muñoz-Barrutia A, Serrano D, Pio R, Montuenga LM, Ortiz-de-Solorzano C.

Integr Biol (Camb). 2013 Feb;5(2):402-13. doi: 10.1039/c2ib20219k.

PMID:
23233094

Supplemental Content

Loading ...
Support Center